Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be participating at the 15th edition of the European Large & Midcap Event, a conference dedicated to meetings between European listed companies and institutional investors, to be held in Paris on October 7 & 8, 2015.
On that occasion, Lionel Ségard, Chairman and ceo of Quantum Genomics, and Marc Karako, Chief Financial Officer, will comment on the Company's latest progress, in particular the Phase IIa clinical trials currently under way for high blood pressure of its drug candidate QGC001 and in preparation stage for the treatment of heart failure.
QGC001 is the first of a new class of therapeutics for the treatment of complicated/resistant hypertension, called Brain Aminopeptidase A Inhibitors (BAPAIs). The objective of QGC001 is to offer an alternative therapy for the treatment of high blood pressure, aimed particularly at patients with a Low Renin High Vasopressin (LRHV) hormonal profile.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication
+33 1 53 67 36 73
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, Inserm, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).